Share >  
Share
Share on Tumblr

Natco Pharma

News »

   latest by relevance
Natco Pharma up 5% on huge volume
Apr 01, 2013 at 16:29 | Source: Moneycontrol.com
At 13:30 hrs Natco Pharma was quoting at Rs 450.25, up Rs 21.20, or 4.94%. It has touched an intraday high of Rs 475.05 and an intraday low of Rs 433.25.
Buy Natco Pharma; target of Rs 473: Firstcall Research
Apr 01, 2013 at 11:31 | Source: Moneycontrol.com
Firstcall Research is bullish on Natco Pharma and has recommended buy rating on the stock with a target price of Rs 473 in its March 30, 2013 research report.
Delhi HC allows Natco to sell Sunitinib, shares up 6%
Mar 20, 2013 at 15:39 | Source: Moneycontrol.com
Healthcare firm Natco Pharma rallied nearly 6 percent to hit an intraday high of Rs 446.75 on Wednesday after the Delhi High Court allowed the company to manufacture and sell anti-cancer drug Sunitinib.
Stocks in news: Asian Paints, 3M India, IFCI, Natco, Bharti
Mar 20, 2013 at 08:34 | Source: CNBC-TV18
Asian Paints | Lloyds Steel | 3M India | PNB | IFCI | SAIL | Natco Pharma | M&M and Bharti Airtel are stocks, which are in the news today.
Bayer to challenge India's patent office order on Nexavar
Mar 07, 2013 at 15:53 | Source: PTI
Bayer AG has said it will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to India's Natco Pharma to make and sell a low-cost generic of the German drug major's patented cancer drug Nexavar.
Natco Pharma gains on patent ruling
Mar 05, 2013 at 11:26 | Source: Reuters
NATCO-PHARMA-GAINS-ON-PATENT-RULING:Natco Pharma gains on patent ruling

Videos »
See Rs 20-25cr in revenue/quarter from Lanzoprazol: Natco
Exit Natco Pharma: Sukhani
Will maintain API growth inline with Q2FY13: Natco Pharma
Cipla's price cut is strategic move: Expert
Cancer drug wars! Cipla slashes prices
more »

Photos »

  /  
News across the web »
Dr Reddy’s says ‘have factored in the impact’
Hyderabad, May 17: Pharma major Dr Reddy’s Laboratories Ltd said the new pricing policy might impact 3-4 per cent of its finished dosage sales in the domestic market. The Department of Pharmace...
May 18, 2013 at 00:17 | Source: The Hindu BusinessLine
Novartis patent row: US 'concerned' over India's patent norms, innovation
Washington: Raising questions over innovation climate in India, the US has said the recent decision by India's Supreme Court to prohibit patent of Novartis' cancer drug Glivec could "preclude iss...
May 02, 2013 at 15:04 | Source: FirstPost
Launch of patented drugs could be delayed in India. Here's why
Launch of patented drugs in India could be delayed due to the government's "thought process on linking patented drug prices to the country's per-capita income", according to a report by cons...
May 02, 2013 at 14:08 | Source: FirstPost
Patented drug entry could be delayed in India: Deloitte
New Delhi, May 1: Launch of patented drugs in India could be delayed due to the government’s “thought process on linking patented drug prices to the country’s per—capita incom...
May 01, 2013 at 19:07 | Source: The Hindu BusinessLine
In the ‘pharmacy of the world’
Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like ...
Apr 29, 2013 at 00:51 | Source: The Hindu BusinessLine
more »
Interact & exchange stock tips & market info »

Expert Chartist

Platinum Member

8186 Followers

Natco Pharma  

At 11:52 hrs Natco Pharma has formed a bullish bar rever...

12.00 PM May 16th

Expert Chartist

Platinum Member

8186 Followers

Natco Pharma  

At 09:58 hrs Natco Pharma has moved above its 150 day si...

10.00 AM May 16th

Expert Chartist

Platinum Member

8186 Followers

Natco Pharma  

At 09:58 hrs Natco Pharma has moved above its 50 day and...

10.00 AM May 15th

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window